{"id":924,"date":"2026-05-25T03:50:03","date_gmt":"2026-05-25T03:50:03","guid":{"rendered":"https:\/\/wuhantopmiraclepeptides.com\/?post_type=product&p=924"},"modified":"2026-06-22T05:27:45","modified_gmt":"2026-06-22T05:27:45","slug":"mod-grf-1-29-ipamorelin-blend-10mg","status":"publish","type":"product","link":"https:\/\/wuhantopmiraclepeptides.com\/index.php\/product\/mod-grf-1-29-ipamorelin-blend-10mg\/","title":{"rendered":"Mod GRF 1-29 & Ipamorelin Blend (10mg)"},"content":{"rendered":"

Mod GRF 1-29 & Ipamorelin Blend (10mg): A Dual-Pathway Research Tool for Growth Hormone Studies<\/span><\/h1>\n

If your research explores the hypothalamic-pituitary-somatotropic axis, the dynamics of growth hormone (GH) secretion, or the downstream effects of insulin-like growth factor 1 (IGF-1), the\u00a0<\/span>Mod GRF 1-29 & Ipamorelin Blend (10mg)<\/span><\/strong>\u00a0offers a precisely defined, dual\u2011pathway experimental platform. This 10 mg formulation combines two well\u2011characterised GH secretagogues\u2014<\/span>Mod GRF 1-29<\/span><\/strong>, a modified analog of growth hormone-releasing hormone (GHRH), and\u00a0<\/span>Ipamorelin<\/span><\/strong>, a selective ghrelin receptor agonist. <\/span><\/p>\n

By targeting two distinct receptors that converge at the pituitary level, this blend allows researchers to model the synergistic interplay between the GHRH and ghrelin systems, providing deeper insight into the regulatory circuits that govern GH pulsatility<\/span>.<\/span><\/p>\n

At\u00a0<\/span>Wuhan Top Miracle Peptides<\/span><\/strong>, we supply high\u2011purity\u00a0<\/span>Mod GRF 1-29 & Ipamorelin Blend (10mg)<\/span><\/strong>\u00a0to research institutions and wholesale buyers across the\u00a0<\/span>United Kingdom, France, Germany, Spain, Sweden, Italy, and the USA<\/span><\/strong>. Every batch is lyophilised, HPLC\u2011verified to \u226598% purity, and accompanied by a Certificate of Analysis (COA), ensuring your investigations into GH regulation, IGF\u20111 signalling, and metabolic research begin with uncompromising quality.<\/span><\/p>\n

What Is the Mod GRF 1-29 & Ipamorelin Blend and How Does It Work?<\/span><\/h2>\n

To fully appreciate the research potential of the\u00a0<\/span>Mod GRF 1-29 & Ipamorelin Blend (10mg)<\/span><\/strong>, it is essential to understand the distinct yet complementary mechanisms of its two components.<\/span><\/p>\n

Mod GRF 1-29: The Stabilised GHRH Analog<\/span><\/h3>\n

Mod GRF 1\u201129, also referred to as\u00a0<\/span>CJC-1295 without DAC<\/span><\/strong>, is a modified analog of growth hormone-releasing hormone (GHRH)<\/span>. It is a 29\u2011amino\u2011acid peptide that retains the shortest fully functional fragment of GHRH, also known by its standardized name, sermorelin<\/span>. The key structural modification involves the substitution of D\u2011Alanine at the second amino acid position, which protects the peptide from enzymatic degradation and increases its resistance to proteolysis<\/span>. This results in enhanced stability and a longer duration of action compared to endogenous GHRH<\/span>. <\/span><\/p>\n

Mod GRF 1\u201129 is hypothesised to bind to GHRH receptors on somatotropic cells in the anterior pituitary gland, supporting the synthesis and pulsatile release of growth hormone<\/span>. The form without DAC has a shorter half\u2011life and supports a pulsatile release pattern that replicates the natural secretion of growth hormone<\/span>.<\/span><\/p>\n

Ipamorelin: The Selective Ghrelin Receptor Agonist<\/span><\/h3>\n

Ipamorelin is a synthetic pentapeptide that selectively activates the growth hormone secretagogue receptor subtype 1a (GHS-R1a)<\/span>. This receptor is the same receptor that ghrelin, the endogenous hunger and GH-releasing hormone, activates<\/span>. Ipamorelin’s defining pharmacological advantage is GH stimulation without elevating cortisol, ACTH, or prolactin, even at doses 200-fold above the GH-release ED\u2085\u2080<\/span>. Its selectivity theoretically reduces unwanted endocrine effects compared to non-selective secretagogues<\/span>. A 1998 paper in the\u00a0<\/span>European Journal of Endocrinology<\/span><\/em>\u00a0first described ipamorelin as “the first selective growth hormone secretagogue”<\/span>.<\/span><\/p>\n

Mechanism of Synergy: Dual\u2011Pathway Activation<\/span><\/h3>\n

The scientific rationale for combining Mod GRF 1\u201129 and Ipamorelin lies in their convergent yet distinct mechanisms<\/span>:<\/span><\/p>\n

    \n
  • \n

    Mod GRF 1\u201129<\/span><\/strong>\u00a0provides the primary stimulus to initiate GH synthesis and release by activating the classical GHRH receptor pathway<\/span>.<\/span><\/p>\n<\/li>\n

  • \n

    Ipamorelin<\/span><\/strong>\u00a0enhances the amplitude of that response by engaging the ghrelin\/secretagogue receptor system<\/span>.<\/span><\/p>\n<\/li>\n

  • \n

    Convergent Signalling:<\/span><\/strong>\u00a0Both pathways converge at the pituitary level, where their combined activation can produce synergistic actions, potentially amplifying GH pulse amplitude and duration<\/span>.<\/span><\/p>\n<\/li>\n<\/ul>\n

    This dual\u2011pathway activation has been shown to increase growth hormone release through complementary mechanisms. Research indicates that a GHRH analog can result in a significant increase (107% and 70% in men and women, respectively) in the 12\u2011hour integrated GH secretion<\/span>. The combination is commonly studied in experimental models for potential synergistic effects on pulsatile growth hormone release<\/span>.<\/span><\/p>\n

    Key Research Applications for the Mod GRF 1\u201129 & Ipamorelin Blend (10mg)<\/span><\/h2>\n

    The\u00a0<\/span>Mod GRF 1-29 & Ipamorelin Blend (10mg)<\/span><\/strong>\u00a0is a versatile tool with applications spanning several domains of endocrinological and metabolic research<\/span>.<\/span><\/p>\n

    1. Growth Hormone Axis & Pituitary Function Studies<\/span><\/h3>\n

    This blend provides a powerful model for investigating the hypothalamic\u2011pituitary\u2011somatotropic axis. Researchers can use it to study:<\/span><\/p>\n